💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadUnlock them all

Valeant seriously considering the sale of neuro assets

Published 2015-10-19, 09:13 a/m
© Reuters.  Valeant seriously considering the sale of neuro assets
PSON
-
BHC
-

NEW YORK, Oct 19 (Reuters) - Valeant Pharmaceuticals (N:VRX)
International VRX.TO said on Monday that it is considering the
sale of its neurological pharmaceutical business and may also
spin it off or take it private.
Valeant CEO J. Michael Pearson (L:PSON) said that the company is
continuing to look at acquisitions, such as for "durable" assets
that would fit with its Bausch & Lomb eyecare business.
He said he would look at cash deals but that using the
company's stock is not an option as it seeks to lower its debt
ratios. He said that buying back shares may be a better use of
the company's money at current prices. Valeant shares were
trading at $174 on Monday before the market opened, down from
its year high of $263.70 on Aug. 5.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.